Albireo Pharma — Corporate Update (October 2022)
18 slides from Albireo Pharma's corporate update, Oct 11, 2022
Slide 1: ASSERT Topline Data Results
©2022 Albireo Pharma, Inc. All rights reserved For Media & Investors Only ASSERT Topline Data Results ASSERT: Phase 3 study evaluating the safety and efficacy of Bylvay ® (odevixibat) in patients with Alagille syndrome October 2022 (Nasdaq: ALBO) For Media & Investors Only
Slide 2: Forward Looking Statements
©2022 Albireo Pharma, Inc. All rights reserved For Media & Investors Only 2 Forward Looking Statements This presentation includes “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 19 95. Forward - looking statements include statements, other than st
Slide 3: On the Call Today
©2022 Albireo Pharma, Inc. All rights reserved For Media & Investors Only 3 On the Call Today Ron Cooper President and CEO Jan Mattsson, PhD Chief Scientific Officer, Head of R&D , & Co - Founder Nadia Ovchinsky, MD, MBA, FAALSD The Children’s Hospital at Montefiore Principal Investigator, ASSERT St
Slide 4: Positive Topline Data Results: Bylvay in Alagille Syndrome Patients
©2022 Albireo Pharma, Inc. All rights reserved For Media & Investors Only 4 POSITIVE TOPLINE DATA RESULTS Bylvay ® (odevixibat) in Alagille S yndrome Patients ©2022 Albireo Pharma, Inc. All rights reserved For Media & Investors Only
Slide 5: Significant Cholestatic Liver Disease Opportunity
©2022 Albireo Pharma, Inc. All rights reserved For Media & Investors Only 5 ©2022 Albireo Pharma, Inc. All rights reserved For Media & Investors Only Significant Cholestatic Liver Disease Opportunity Three Bylvay Phase 3 Gold Standard Studies *Worldwide Prevalence: Top 25 Markets excluding China and
Slide 6: Alagille Syndrome is a Devastating Disease
©2022 Albireo Pharma, Inc. All rights reserved For Media & Investors Only 6 Alagille Syndrome is a Devastating Disease May present in the first 3 months of life Cholestasis is the most common feature, typically presenting with unremitting pruritus Causes quality of life impairments including growth
Slide 7: ASSERT Phase 3 Study Design
©2022 Albireo Pharma, Inc. All rights reserved For Media & Investors Only 7 ©2022 Albireo Pharma, Inc. All rights reserved For Media & Investors Only ASSERT: Global Phase 3 Pivotal Study Key Inclusion Criteria: • Patient of any age with genetically confirmed diagnosis of ALGS • History of significan
Slide 8: Key Baseline Demographics & Characteristics
©2022 Albireo Pharma, Inc. All rights reserved For Media & Investors Only 8 ©2022 Albireo Pharma, Inc. All rights reserved For Media & Investors Only Key Baseline Demographics & Characteristics Age (years); mean (SD) 5.40 (4.411) 6.73 (3.780) Sex (% female) 64.7 40.0 Serum bile acids (µmol/L); mean
Slide 9: Highly Statistically Significant Change in Pruritus and Serum Bile Acids
©2022 Albireo Pharma, Inc. All rights reserved For Media & Investors Only 9 ©2022 Albireo Pharma, Inc. All rights reserved For Media & Investors Only Highly Statistically Significant Change in Pruritus and Serum Bile Acids 1. LS Mean at weeks 21 - 24 2. LS Mean at weeks 20 and 24 24 - week treatment
Slide 10: Early, Rapid, Sustained Pruritus Improvements
©2022 Albireo Pharma, Inc. All rights reserved For Media & Investors Only 10 ©2022 Albireo Pharma, Inc. All rights reserved For Media & Investors Only Early, Rapid, Sustained Pruritus Improvements Change from Baseline 1 *** *** ** *** ** ** 1. LS Mean (95% CI) At all time points, early, rapid and su
Slide 11: Profound Sleep Improvements Over Time
©2022 Albireo Pharma, Inc. All rights reserved For Media & Investors Only 11 ©2022 Albireo Pharma, Inc. All rights reserved For Media & Investors Only Profound Sleep Improvements Over Time 1 At all time points, Bylvay treatment led to fewer days sleeping with a caregiver 1. Secondary Endpoint 2. LS
Slide 12: Substantial Improvement in Multiple Sleep Parameters
©2022 Albireo Pharma, Inc. All rights reserved For Media & Investors Only 12 ©2022 Albireo Pharma, Inc. All rights reserved For Media & Investors Only Substantial Improvement in Multiple Sleep Parameters • Days with help falling asleep (p=0.003) • Days with soothing (p<0.0001) • Days sleeping with c
Slide 13: Safety: Incidence of Diarrhea and Adverse Events
©2022 Albireo Pharma, Inc. All rights reserved For Media & Investors Only 13 ©2022 Albireo Pharma, Inc. All rights reserved For Media & Investors Only Well Tolerated with a Low Incidence of Diarrhea Adverse events 12 (70.6) 26 (74.3) Serious adverse events 2 (11.8) 5 (14.3) Drug Related TEAEs in ≥5%
Slide 14: Bylvay ASSERT Phase 3 Results Summary
©2022 Albireo Pharma, Inc. All rights reserved For Media & Investors Only 14 ©2022 Albireo Pharma, Inc. All rights reserved For Media & Investors Only Bylvay ASSERT Phase 3 Results Summary DIVERSE , GLOBAL STUDY POPULATION Trial enrolled patients from birth to young adults with both JAG1 and NOTCH2
Slide 15: Nadia Ovchinsky, Principal Investigator, ASSERT Study
©2022 Albireo Pharma, Inc. All rights reserved For Media & Investors Only 15 Nadia Ovchinsky , MD, MBA, FAALSD Director of Pediatric Hepatology Medical Director of Pediatric Liver Transplantation , Children's Hospital at Montefiore Professor of Pediatrics , Albert Einstein College of Medicine Nadia
Slide 16: Gold Standard Phase 3 Studies
©2022 Albireo Pharma, Inc. All rights reserved For Media & Investors Only 16 ©2022 Albireo Pharma, Inc. All rights reserved For Media & Investors Only Gold Standard Phase 3 Studies 1 st IBATi Phase 3 ALGS Study Pruritus endpoint (p=0.002) Bile acids endpoint (p=0.001) Diarrhea vs placebo (11.4% vs 5
Slide 17: Bylvay Plans and Priorities
©2022 Albireo Pharma, Inc. All rights reserved For Media & Investors Only 17 Bylvay Plans and Priorities Strong financial foundation with over $ 270 million of cash US and Europe Regulatory Filings Q1 2023 Biliary Atresia Phase 3 Study Full Enrollment Q4 2022 Generate PFIC Sales Launch in Additional
Slide 18: ASSERT Topline Data Results
©2022 Albireo Pharma, Inc. All rights reserved For Media & Investors Only ASSERT Topline Data Results ASSERT: Phase 3 study evaluating the safety and efficacy of Bylvay ® (odevixibat) in patients with Alagille syndrome October 2022 (Nasdaq: ALBO) For Media & Investors Only